Tumour immunity: effector response to tumour and role of the microenvironment
- PMID: 18275997
- DOI: 10.1016/S0140-6736(08)60241-X
Tumour immunity: effector response to tumour and role of the microenvironment
Abstract
Substantial evidence shows that inflammation promotes oncogenesis and, occasionally, participates in cancer rejection. This paradox can be accounted for by a dynamic switch from chronic smouldering inflammation promoting cancer-cell survival to florid, tissue-disruptive inflammatory reactions that trigger cancer-cell destruction. Clinical and experimental observations suggest that the mechanism of this switch recapitulates the events associated with pathogen infection, which stimulate immune cells to recognise danger signals and activate immune effector functions. Generally, cancers do not have danger signals and, therefore, they cannot elicit strong immune reactions. Synthetic molecules have been developed that mimic pathogen invasion at the tumour site. These compounds activate dendritic cells to produce proinflammatory cytokines, which in turn trigger cytotoxic mechanisms leading to cancer death. Simultaneously, dendritic cells capture antigen shed by dying cancer cells, undergo activation, and stimulate antigen-specific T and B cells. This process results in massive amplification of the antineoplastic inflammatory process. Thus, although anti-inflammatory drugs can prevent onset of some malignant diseases, induction of T cells specific for tumour antigen by active immunisation, combined with powerful activation signals within the cancer microenvironment, might yield the best strategy for treatment of established cancers.
Similar articles
-
Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.Scand J Immunol. 2004 Jul-Aug;60(1-2):143-52. doi: 10.1111/j.0300-9475.2004.01435.x. Scand J Immunol. 2004. PMID: 15238083
-
Genetically modified tumour vaccines--where we are today.Cancer Treat Rev. 1999 Feb;25(1):29-46. doi: 10.1053/ctrv.1998.0104. Cancer Treat Rev. 1999. PMID: 10212588 Review.
-
Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.Immunobiology. 2012 Jul;217(7):719-29. doi: 10.1016/j.imbio.2011.12.001. Epub 2011 Dec 8. Immunobiology. 2012. PMID: 22305004
-
Immunogenic anti-cancer chemotherapy as an emerging concept.Curr Opin Immunol. 2008 Oct;20(5):545-57. doi: 10.1016/j.coi.2008.05.008. Epub 2008 Jun 23. Curr Opin Immunol. 2008. PMID: 18573339 Review.
-
Antigen presentation at the inflammatory site.Crit Rev Immunol. 1989;9(4):313-62. Crit Rev Immunol. 1989. PMID: 2679663 Review.
Cited by
-
Immunotherapy of cancer in 2012.CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. CA Cancer J Clin. 2012. PMID: 22576456 Free PMC article. Review.
-
The Role of Stroma in Tumor Development.Cancer J. 2015 Jul-Aug;21(4):250-3. doi: 10.1097/PPO.0000000000000127. Cancer J. 2015. PMID: 26222075 Free PMC article. Review.
-
Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer.FEBS Open Bio. 2015 May 12;5:502-7. doi: 10.1016/j.fob.2015.05.003. eCollection 2015. FEBS Open Bio. 2015. PMID: 26137435 Free PMC article.
-
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.Obstet Gynecol. 2016 Jul;128(1):127-137. doi: 10.1097/AOG.0000000000001491. Obstet Gynecol. 2016. PMID: 27275802 Free PMC article.
-
Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment.Int J Breast Cancer. 2012;2012:716564. doi: 10.1155/2012/716564. Epub 2011 Nov 9. Int J Breast Cancer. 2012. PMID: 22295250 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources